By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab-bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.
With a median age of 72 years at first diagnosis, chronic lymphocytic leukaemia (CLL) is a disease o...
19Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). Howev...
Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymp...
By using the GRADE system we produced the following recommendations for the use of bendamustine in t...
By using the GRADE system we produced the following recommendations for the use of bendamustine in t...
Bendamustine has achieved widespread international regulatory approval and is a standard agent for t...
The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, a...
Purpose We investigated the safety and efficacy of bendamustine and rituximab (BR) in previously unt...
Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl)...
Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl)...
Efficacy and Safety of Bendamustine and Rituximab As First Salvage Treatment in Chronic Lymphocytic ...
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chloramb...
Purpose The objective of this trial was to evaluate safety and efficacy of bendamustine combined wit...
Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). However...
Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). However...
With a median age of 72 years at first diagnosis, chronic lymphocytic leukaemia (CLL) is a disease o...
19Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). Howev...
Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymp...
By using the GRADE system we produced the following recommendations for the use of bendamustine in t...
By using the GRADE system we produced the following recommendations for the use of bendamustine in t...
Bendamustine has achieved widespread international regulatory approval and is a standard agent for t...
The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, a...
Purpose We investigated the safety and efficacy of bendamustine and rituximab (BR) in previously unt...
Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl)...
Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl)...
Efficacy and Safety of Bendamustine and Rituximab As First Salvage Treatment in Chronic Lymphocytic ...
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chloramb...
Purpose The objective of this trial was to evaluate safety and efficacy of bendamustine combined wit...
Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). However...
Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). However...
With a median age of 72 years at first diagnosis, chronic lymphocytic leukaemia (CLL) is a disease o...
19Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). Howev...
Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymp...